Cidara Therapeutics, Inc. (CDTX)

Market Cap	2.65B
Revenue (ttm)	n/a
Net Income (ttm)	-184.74M
Shares Out	25.36M
EPS (ttm)	-11.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	954,488
Open	98.29
Previous Close	98.64
Day's Range	95.87 - 105.00
52-Week Range	12.74 - 121.21
Beta	1.55
Analysts	Strong Buy
Price Target	127.25 (+21.9%)
Earnings Date	Nov 6, 2025

About CDTX

Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 15, 2015
• Employees: 38
• Stock Exchange: NASDAQ
• Ticker Symbol: CDTX
• Website: https://www.cidara.com

Financial Performance

In 2024, Cidara Therapeutics's revenue was $1.28 million, a decrease of -94.52% compared to the previous year's $23.28 million. Losses were -$169.83 million, 640.6% more than in 2023.

Analyst Summary

According to 13 analysts, the average rating for CDTX stock is "Strong Buy." The 12-month stock price target is $127.25, which is an increase of 21.90% from the latest price.

Price Target

$127.25

(21.90% upside)

Analyst Consensus: Strong Buy